Levosimendan Altan (Levosimendan)

Levosimendan works by binding to troponin C, making the heart muscle more responsive to calcium, which increases contractile strength without raising intracellular calcium. It also opens ATP‑sensitive potassium channels in blood vessels, causing vasodilation that lowers both preload and afterload, thereby supporting overall cardiac performance.

The dosing regimen for levosimendan is determined by the prescribing clinician based on the patient’s condition, weight, and response. Typically, the drug is given as an intravenous infusion over a set period, but exact rates and duration must be individualized and documented by a qualified healthcare professional.

Safety data for levosimendan during pregnancy and lactation are limited. Because potential risks cannot be ruled out, the drug should only be used if the potential benefit justifies the possible risk to the fetus or infant, and it is generally avoided unless absolutely necessary.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and any required import documentation.

Unlike traditional inotropes that increase intracellular calcium and may raise the risk of arrhythmias, levosimendan enhances contractility by sensitizing troponin C to existing calcium and adds vasodilatory effects. This dual action can improve cardiac output with a potentially lower incidence of calcium‑mediated toxicity compared with agents such as dobutamine.

Levosimendan Altan should be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen. The product should be kept in its original packaging to maintain stability, and any reconstituted solution should be used within the time frame specified by the manufacturer.

Levosimendan is administered intravenously, usually as a continuous infusion after reconstitution of the lyophilised powder. The infusion is given under close clinical monitoring, with adjustments made based on hemodynamic response, blood pressure, and heart rate as directed by the treating physician.

The most serious risks include severe hypotension, ventricular arrhythmias, myocardial ischemia, and rare allergic reactions such as anaphylaxis. Clinicians should monitor blood pressure, ECG, and cardiac enzymes closely, especially in patients with existing coronary disease or electrolyte imbalances.

Levosimendan is contraindicated in patients with known hypersensitivity to the drug, severe hypotension, or uncontrolled ventricular arrhythmias. Caution is also advised for individuals with recent myocardial infarction, severe hepatic impairment, or those receiving other strong vasodilators without appropriate monitoring.